![]() ![]() The term used to define this particular insomnia is Coronasomnia or COVID-19 insomnia. Sleep disorders or insomnia is one of the psychiatric problems that arise during COVID-19 pandemic. In addition, medical care and medication also trigger psychiatric problems. 2ĬOVID-19 patients have the possibility of experiencing psychiatric symptoms or problems due to the impact of diagnosis communication, forced isolation, the medical symptoms caused, and the risk of death. 1 The risk of severity and death from this disease increases in people with old age and comorbidities. COVID-19 is associated with hypoxic respiratory distress and can rapidly progress to acute respiratory distress syndrome (ARDS). COVID-19 patients show diverse clinical presentations ranging from asymptomatic, mild symptoms to severe symptoms characterized by severe respiratory distress. The respiratory tract is the main organ that is affected and disturbed. COVID-19 is a systemic viral infection that attacks many organs and work processes of the body. Among various health fields, psychiatry is a medical field that is also affected by this pandemic. The Coronavirus Disease (COVID-19) pandemic is a condition that requires rapid handling and adjustment, especially in the health sector. Therefore, attention and monitoring of the use of anti-insomnia drugs in COVID-19 patients need to be carried out by considering the side effects and interactions that are very risky. Side effects such as drowsiness and dizziness were among the most commonly reported effects. Meanwhile, the combination of zolpidem, lorazepam, and diphenhydramine improved TST parameters better than other drugs. Orexin receptor antagonist drugs have good efficacy in increasing WASO, LPS, and SE with an acceptable safety profile. Overall anti-insomnia drugs have efficacy in improving sleep parameters. The articles were explored on PubMed and Cochrane Library, whereas the drug–drug interactions between the anti-insomnia and COVID-19 drugs were searched on Interaction Checker and Lexiomp-interact. The literature review aims to make health practitioners aware of the anti-insomnia drugs that have the best efficacy and safety issues that are clinically relevant from the use of anti-insomnia drugs and the interactions of anti-insomnia drugs with various drugs used in the treatment of COVID-19. As with drugs generally, anti-insomnia drugs are associated with various safety issues, especially in people with COVID-19. Anti-insomnia drugs such as hypnotics, sedatives, and anxiolytics are the easiest option. Data show that the prevalence of this problem is increasing, especially in the confirmed COVID-19 patient group. ![]() The term used to define this particular insomnia is coronasomnia or COVID-19 insomnia. Sleep disorders or insomnia is one of the psychiatric problems that arise during the COVID-19 pandemic. Coronavirus disease-19 (COVID-19) is a systemic viral infection. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |